RheumaGen
RheumaGen is a private biotech company dedicated to curing autoimmune diseases at their source, beginning with rheumatoid arthritis (RA). RheumaGen is focused on editing the human leukocyte antigen (HLA) or “immune gene” so that the immune system no longer attacks healthy cells. RheumaGen’s lead program, RG0401, is designed as a one-time curative treatment and looks to make possible what has always been thought of as impossible: transforming autoimmune disease.
